Regeneron Pharmaceuticals shares have surged 21.9% over the past month, outpacing the industry's 4% gain, driven by better-than-expected quarterly results. Eylea HD sales in the United States surged 52% year over year to $596 million in the second quarter of 2026, supported by FDA label expansions including extended dosing intervals of up to every 20 weeks for wet age-related macular degeneration and diabetic macular edema. Dupixent continues to deliver strong growth across key indications, while the oncology portfolio received a boost with the FDA's accelerated approval of Lynozyfic for relapsed or refractory multiple myeloma. Despite the rally, the stock trades at 16.80 times forward earnings, below its five-year mean of 19.67 times, and Zacks Investment Research advises a Hold rating, suggesting investors wait for a better entry point.
